MAIA Biotechnology, Inc. (MAIA) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Chicago, IL, アメリカ. 現CEOは Vlad Vitoc.
MAIA を有する IPO日 2022-07-28, 13 名の正社員, に上場 NYSE, 時価総額 $54.9M.
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.
